首站-论文投稿智能助手
典型文献
Interferon-γinduces immunosuppression in salivary adenoid cystic carcinoma by regulating programmed death ligand 1 secretion
文献摘要:
INTRODUCTION Salivary adenoid cystic carcinoma (SACC) is a common salivary gland malignancy and characterized by low immunogenicity.1–2 The 10-year survival rate of SACC patients is 50%.
文献关键词:
作者姓名:
Qiuyun Fu;Xingchi Liu;Houfu Xia;Yicun Li;Zili Yu;Bing Liu;Xuepeng Xiong;Gang Chen
作者机构:
The State Key Laboratory Breeding Base of Basic Science of Stomatology&Key Laboratory of Oral Biomedicine Ministry of Education,School and Hospital of Stomatology,Wuhan University,Wuhan,China;Department of Oral and Maxillofacial Surgery,School and Hospital of Stomatology,Wuhan University,Wuhan,China;Peking University Shenzhen Hospital,Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center,Shenzhen,China;Frontier Science Center for Immunology and Metabolism,Wuhan University,Wuhan,China
引用格式:
[1]Qiuyun Fu;Xingchi Liu;Houfu Xia;Yicun Li;Zili Yu;Bing Liu;Xuepeng Xiong;Gang Chen-.Interferon-γinduces immunosuppression in salivary adenoid cystic carcinoma by regulating programmed death ligand 1 secretion)[J].国际口腔科学杂志(英文版),2022(04):541-548
A类:
Salivary
B类:
Interferon,induces,immunosuppression,salivary,adenoid,cystic,carcinoma,by,regulating,programmed,death,ligand,secretion,INTRODUCTION,SACC,is,common,gland,malignancy,characterized,low,immunogenicity,year,survival,rate,patients
AB值:
0.708476
相似文献
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
Ming Bai;Meng Wang;Ting Deng;Yuxian Bai;Kai Zang;Zhanhui Miao;Wenlin Gai;Liangzhi Xie;Yi Ba-Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin 300060,China;Department of Gastrointestinal Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Medical Oncology,Henan Cancer Hospital,The Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China;Oncology Department,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China;Sinocelltech Ltd.,Beijing 100176,China;Beijing Engineering Research Center of Protein and Antibody,Beijing 100176,China;Cell Culture Engineering Center,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100176,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis
Liu Jiaye;Tian Ye;Fu Xia;Mu Chunyang;Yao Menglin;Ni Yinyun;Liu Yong;Li Zhihui-Department of Thyroid and Parathyroid Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan 610000, China;Respiratory Health Institute, Frontiers Science Center for Disease Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;Department of Ultrasound, West China Hospital of Sichuan University, Chengdu, Sichuan 610000, China;Department of Outpatients, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;Department of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China;Department of Gastroenterological Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China
Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway
Yonghui Zhang;Haoyang Zhang;Jinage Mu;Meiyue Han;Zhihao Cao;Feng Dong;Tingting Wang;Lian Pan;Wujing Luo;Jiaxin Li;Huan Liu;Lishan Jin;Wenxuan Ding;Yong Wei;Xuesong Deng;Dan Liu;Xiuzhen He;Yi Pang;Xiao Mu;Zhongjun Wu;Dilong Chen-The First Affiliated Hospital of Chongqing Medical University,Chongqing 400042,China;The People's Hospital Affiliated to Chongqing Three Gorges Medical College,Chongqing 404100,China;Chongqing Key Laboratory of Development and Utilization of Genuine Medicinal Materials in Three Gorges Reservoir Area,Chongqing 404120,China;Chongqing Engineering Research Center of Antitumor Natural Drugs,Chongqing 404120,China;Key Laboratory of Intelligent Information Processing and Control,College of Electronic and Information Engineering,Chongqing Three Gorges University,Chongqing 404110,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。